182 related articles for article (PubMed ID: 37332328)
1. Efficacy and safety of pyrotinib in combination with albumin‑bound paclitaxel for the treatment of HER2‑positive advanced breast cancer: A real‑world study.
Yang L; Zheng L; Kong F; Tian X; Zhang S; Pu P
Oncol Lett; 2023 Jul; 26(1):312. PubMed ID: 37332328
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
Wang Y; Xu Y; Liu X; Li C; Wang J; Zhang X; Shao B; Zhang J
Gland Surg; 2024 May; 13(5):654-662. PubMed ID: 38845840
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer.
Zhou Y; Wang H; Yang J; Wang F; Dong D; Zhao X; Wang L; He R; Ruan Z; Yang J
J Chemother; 2024 Apr; ():1-11. PubMed ID: 38557437
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
[TBL] [Abstract][Full Text] [Related]
5. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.
Zhong X; He P; Chen J; Yan X; Wei B; Zhang Z; Bu H; Li J; Tian T; Lv Q; Wang X; Li H; Wang J; Huang J; Suo J; Liu X; Zheng H; Luo T
Gland Surg; 2022 Jan; 11(1):216-225. PubMed ID: 35242683
[TBL] [Abstract][Full Text] [Related]
7. Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
Li Y; Qiu Y; Li H; Luo T; Li W; Wang H; Shao B; Wang B; Ge R
Front Oncol; 2021; 11():664429. PubMed ID: 33996589
[TBL] [Abstract][Full Text] [Related]
8. Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study.
Zhang L; Wu X; Zhou J; Zhu M; Yu H; Zhang Y; Zhao Y; Han Z; Guo Y; Guan X; Wang X; Xu H; Sun L; Zhang J; Zhuang M; Xie L; Yu S; Chen P; Feng J
Front Oncol; 2021; 11():699323. PubMed ID: 34336688
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study.
Zhang X; Li Z; Han L; Lv Z; Teng Y; Cui X; Zhou C; Wu H; Fang W; Xu L; Zhao S; Song C; Zheng Y; Gao T; Li M
Onco Targets Ther; 2022; 15():1067-1078. PubMed ID: 36199295
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis.
Liu J; Sun X; Du Q; Yao J; Dai M; Cheng Q; Xu H; Li Y; Liu X; Zhang M; Zhou Y; Yang Y
Breast Cancer (Dove Med Press); 2022; 14():491-504. PubMed ID: 36575687
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.
Ye G; Chen P; Liu X; He T; Pivot X; Pan R; Zhou D; Zhu L; Zhang K; Li W; Yang S; Lin J; Cai G; Huang H
Gland Surg; 2024 Mar; 13(3):374-382. PubMed ID: 38601287
[TBL] [Abstract][Full Text] [Related]
14. Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.
Sun Y; Chen B; Li J; Peng L; Li S; Yu X; Li L
Cancer Manag Res; 2021; 13():7165-7174. PubMed ID: 34548820
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.
Chen Q; Ouyang D; Anwar M; Xie N; Wang S; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W; Ouyang Q
Front Oncol; 2020; 10():811. PubMed ID: 32528890
[No Abstract] [Full Text] [Related]
16. Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer.
Li Y; Ma X; Zhao Z; Li L; Gao C; Liu D; Li B; Zhao B
Breast Cancer (Dove Med Press); 2022; 14():405-415. PubMed ID: 36510611
[TBL] [Abstract][Full Text] [Related]
17. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
Song Z; Lv D; Chen SQ; Huang J; Li Y; Ying S; Wu X; Hua F; Wang W; Xu C; Bei T; Gao C; Sun Z; Zhang Y; Lu S
Clin Cancer Res; 2022 Feb; 28(3):461-467. PubMed ID: 34753778
[TBL] [Abstract][Full Text] [Related]
18. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.
Gu Q; Zhu M; Wang Y; Gu Y
Breast Cancer (Dove Med Press); 2024; 16():253-268. PubMed ID: 38812479
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
